Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

sipuleucel-T

- PMLiVE

Young diabetes patients in England and Wales receive fewer vital checks

Less than a third with type 1 diabetes receive eight of nine recommended care processes

- PMLiVE

Pfizer targets women in Viagra campaign

Hope a female voice will encourage men to seek treatment for erectile dysfunction

- PMLiVE

NICE recommends Lundbeck’s alcohol dependency drug

NHS patients to have access to Selincro to help control drinking

- PMLiVE

Pfizer takes to Tumblr to share employee stories

New blog promotes their contributions to health

National Institute for Health and Care Excellence NICE logo

Remicade, Humira and Simponi face NICE knock-back

Draft guidance does not recommend the drugs for ulcerative colitis

- PMLiVE

NICE backs Celgene’s Revlimid in rare blood cancer

Patient access scheme sways the HTA body

- PMLiVE

BMS and Pfizer to donate $1m for cardiovascular education

The money will be distributed between seven organisations

- PMLiVE

NICE fast-tracks GSK’s skin cancer drug Tafinlar

But only on condition the company cuts its price

- PMLiVE

Pfizer acquires option to license potential Parkinson’s treatment

Medgenesis cuts exclusive deal for its GDNF treatment

National Institute for Health and Care Excellence NICE logo

NICE wants greater access to clinical data

Will turn to European regulators if companies fail to provide information

- PMLiVE

NICE knocks back Celgene’s Abraxane in pancreatic cancer

Says cancer drug's cost not justified by its limited benefit

- PMLiVE

England’s Cancer Drugs Fund: Naughty or NICE?

The decision to extend the CDF raises questions on the future of cancer drug access on the NHS

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links